$AUPH - On our trading list. Congrats if you doubled your money today! Not sure what to make of it from here after being up as much as 110% in pre-market trades. As we don't like to chase anything we have missed.Aurinia Pharmaceuticals price target raised to $20 from $11 at RBCCapital RBC Capital analyst Douglas Miehm raised his price target on Aurinia Pharmaceuticals to $20 and kept his Outperform rating after a "robust" read-out for its Phase 3 voclosporin trial data in lupus nephritis, which demonstrated a superior profile over the standard of care. The analyst notes that the the risk profile for the company has "improved significantly" with the release, expecting Aurinia to gain approval for voclosporin in late 2020/early 2021 with a launch coming some time in 2021.Aurinia Pharmaceuticals price target raised to $22 from $14 at Oppenheimer.Oppenheimer analyst Justin Kim raised his price target for Aurinia Pharmaceuticals to $22 from $14 following the release of top-line Phase 3 AURORA results with voclosporin in lupus nephritis. In a research note to investors, Kim says that in addition to establishing strong efficacy benefit in complete renal response rate, a robust tolerability and safety profile was presented. In light of these data, Kim says he expects focus to quickly shift to the large addressable commercial potential in LN and regulatory timelines. $AUPH, Aurinia Pharmaceuticals Inc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page